Escend Pharmaceuticals
Manufacturing · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
3475 Edison Way Ste R, Menlo Park, Calif...Phone Number
(650) 241-9128Website
www.escendpharma.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Escend Pharmaceuticals
Escend Pharmaceuticals specializes in developing novel therapeutics targeting cancer stem cells, focusing on oncology orphan indications. Their lead drug, ES-3000, aims to improve treatment outcomes for patients with acute myeloid leukemia and other cancers by reducing leukemic stem cells and enhancing the effectiveness of existing treatments. The company also works on ES-4000, which targets solid tumors like pancreatic and lung cancers. Escend's innovative approach seeks to provide alternatives to conventional therapies that often have significant side effects and limited efficacy.Explore more
Popular SearchesEscend Pharmaceuticals IncEscend Technologies LLCEscend PharmaceuticalsSIC Code 28,283NAICS Code 32,325Show moreEscend Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Escend Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Escend Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Escend Pharmaceuticals has new funding data
Check if Escend Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Check out if Escend Pharmaceuticals is spiking on competitors!
Website visits: Recent activity has been detected on your website
Click to see if Escend Pharmaceuticals had a recent Job posting/layoffs
Product Launch: Get notified when Escend Pharmaceuticals launches new products
Congratulate Masked Content for being promoted to Masked Content at Escend Pharmaceuticals
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Escend Pharmaceuticals recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined Escend Pharmaceuticals as Masked Content
Find 2 more new buyers
Compare Similar Companies to Escend Pharmaceuticals
Compare insights from companies similar to Escend Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Escend Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Escend Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Escend Pharmaceuticals.
Escend Pharmaceuticals Tech Stack
A closer look at the technologies used by Escend Pharmaceuticals
Escend Pharmaceuticals News & Media
Escend Pharmaceuticals, Inc., Receives IND Clearance from the FDA for ES-3000 Phase I Study in Relapsed or Refractory Acute Myeloid Leukemia (AML)
Escend announces IND clearance for ES-3000 phase I study in relapsed or refractory (R/R) acute myeloid leukemia (AML) MENLO PARK, Calif., July 15, 2022 /PRNewswire/ -- Escend Pharmaceuticals, Inc., a privately held company focused on the development of small molecule therapeutics for...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Escend Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Escend Pharmaceuticals specializes in developing novel therapeutics targeting cancer stem cells, focusing on oncology orphan indications. Their lead drug, ES-3000, aims to improve treatment outcomes for patients with acute myeloid leukemia and other cancers by reducing leukemic stem cells and enhancing the effectiveness of existing treatments. The... Read More
